Kv4.2 is the pore-forming component of A-type potassium channels expressed prominently in dendrites, where the channels constrain excitability and influence the integration of incoming signals. These channels operate within larger complexes that include regulatory proteins such as the KChIP family and the membrane-associated subunits DPP6 and DPP10. DPP6 is particularly important in hippocampal CA1 pyramidal neurons: it supports channel surface expression, alters conductance and inactivation, and helps establish the increase in Kv4.2 abundance from the cell body toward distal dendrites. The new study used wild-type mice, mice lacking maternal UBE3A expression to model Angelman syndrome, and separate DPP6 knockout mice to distinguish the effects of the two proteins.

The first set of experiments asked where the UBE3A ubiquitin ligase encounters Kv4.2. Researchers tagged Kv4.2 with a binding site for alpha-bungarotoxin, allowing them to label channels that were present on the surface of living cells. In HEK293T cells expressing the tagged channel and UBE3A, surface-labeled Kv4.2 showed little colocalization with UBE3A when membrane trafficking was restricted at 4 degrees Celsius. When the labeled cells were returned to 37 degrees Celsius, permitting internalization and intracellular movement, Kv4.2–UBE3A colocalization increased markedly. A biochemical version of the experiment produced the same pattern: recovery of UBE3A with surface-tagged Kv4.2 was barely detectable under restricted trafficking but rose after incubation allowed endocytosis, with more UBE3A recovered at 50 minutes than at 20 minutes.

These observations place UBE3A downstream of channel internalization rather than showing that it constitutively binds channels at the plasma membrane. That fits earlier work in which neuronal activity promotes phosphorylation of Kv4.2 at threonine 607, recruitment of the prolyl isomerase Pin1, dissociation from DPP6 and subsequent UBE3A-dependent degradation. The current results refine the sequence: activity-associated remodeling is followed by endocytosis, after which UBE3A preferentially processes the internalized channel pool. The study did not directly image the accumulation of such a pool in Angelman syndrome neurons, so that part of the proposed mechanism remains a model that requires further testing.

In hippocampal tissue from UBE3A-deficient “AS” mice, the amount of DPP6 and its distribution among synaptosomal, postsynaptic-density and non-postsynaptic-density fractions were unchanged relative to wild-type littermates. Co-immunoprecipitation also found no detectable association between UBE3A and DPP6 in transfected cells, arguing against a simple model in which UBE3A regulates DPP6 by binding it directly. By contrast, the amount of DPP6 associated with Kv4.2 was significantly reduced in AS mice. The interaction between Kv4.2 and KChIP proteins was unaffected, indicating that loss of UBE3A did not broadly dismantle every interaction between Kv4.2 and its auxiliary subunits.

Seizure induction with pentylenetetrazole provided an activity-dependent test of the complex. In wild-type mice, pentylenetetrazole at 60 mg/kg reduced Kv4.2–DPP6 association after 30 minutes, as expected from the established model of activity-induced channel remodeling. The same treatment did not produce a significant additional reduction in AS mice, whose association was already reduced. Basal phosphorylation of Kv4.2 at threonines 602 and 607 was normal in AS mice, and seizure-induced phosphorylation at threonine 607 remained intact. The defect therefore appears to lie after the principal phosphorylation response rather than in the basal phosphorylation signal itself, although AS mice showed an additional increase in threonine-602 phosphorylation after seizure induction that was not seen in wild-type animals.

DPP6 knockout mice displayed a different molecular phenotype, helping show that the auxiliary subunit is not merely a passive partner. Basal phosphorylation at both threonine 602 and threonine 607 was elevated in DPP6-deficient tissue, while the phosphorylation increase normally triggered by pentylenetetrazole was absent. Phosphorylation of p38 MAPK, the kinase associated with the two threonine sites, remained normal at baseline and after treatment, suggesting that upstream kinase activation was intact. The authors interpret the findings as evidence of reciprocal regulation: activity-dependent phosphorylation promotes dissociation from DPP6, while DPP6 helps organize a channel complex capable of appropriate phosphorylation dynamics. This distinction is important because the AS phenotype involves altered complex remodeling with largely preserved basal phosphorylation, whereas removing DPP6 alters the phosphorylation pattern itself.

Immunostaining then connected the biochemical changes to dendritic structure. Kv4.2 protein normally forms a proximal-to-distal gradient along both apical and basal dendrites of CA1 pyramidal neurons. The researchers quantified staining about 10 micrometers from the stratum pyramidale and at more distant sites, including 130 micrometers in stratum radiatum and 70 micrometers in stratum oriens. That gradient was significantly impaired in DPP6 knockout mice on both apical and basal dendrites, consistent with an earlier electrophysiological finding that DPP6 is required for the corresponding increase in A-type potassium current toward distal dendrites. The imaging results therefore show that the electrical gradient has a matching protein-distribution component.

UBE3A-deficient mice also had impaired Kv4.2 gradients along both sets of CA1 dendrites. Kainic-acid-induced seizures altered the distribution in wild-type mice, whereas AS mice showed a loss of the gradient in stratum oriens but a significantly smaller seizure-associated change than wild-type littermates. This reduced responsiveness suggests that UBE3A-deficient neurons have less capacity to redistribute Kv4.2 in response to increased activity. Their basal distribution resembled the remodeled pattern seen after seizure induction in wild-type animals, raising the possibility that loss of UBE3A leaves neurons in a persistently shifted trafficking state. The findings do not establish that this mechanism directly causes seizures, cognitive impairment or other features of Angelman syndrome, and the experiments were conducted in animals and cultured cells rather than patients.

Kv4.2 normally limits dendritic excitability and helps shape the propagation and integration of excitatory signals. Its disrupted organization could therefore have effects beyond the biochemical status of the channel complex, especially given the hyperexcitability and seizure susceptibility associated with Angelman syndrome. The results also reconcile, at least partly, the previously reported increase in somatic A-type current in AS mice with the impaired dendritic gradient found here: greater overall Kv4.2 abundance could raise somatic currents, while weakened DPP6 association could disturb the channel’s normal spatial distribution. The study identifies post-endocytic Kv4.2 processing as a new mechanistic link between UBE3A deficiency and dendritic ion-channel dysfunction, but whether restoring complex assembly, trafficking or distribution would improve symptoms remains untested.

Subject of Research: Kv4.2–DPP6 channel-complex dynamics and dendritic organization in an Angelman syndrome mouse model

Article Title: Impaired Kv4.2-DPP6 complex dynamics in a mouse model of Angelman syndrome

Article References: Hu, J.-H., Liu, Y., Malloy, C., & Hoffman, D. A. (2026). Impaired Kv4.2-DPP6 complex dynamics in a mouse model of Angelman syndrome. Frontiers in Cellular Neuroscience, 20, Article 1953686. https://doi.org/10.3389/fncel.2026.1953686

Image Credits: AI Generated

DOI: 10.3389/fncel.2026.1953686

Keywords: Angelman syndrome, UBE3A, Kv4.2, DPP6, dendritic excitability, hippocampus, ion channels, membrane trafficking, mouse model, neuronal hyperexcitability, Impaired, complex

The hippocampus is the brain’s primary memory-encoding structure, and its CA1 and CA3 regions are critical for both storing new information and retrieving stored patterns. Long-term potentiation (LTP), the strengthening of synaptic connections that underlies memory formation, depends heavily on NMDA receptors—ion channels that open in response to glutamate binding and postsynaptic depolarization, allowing calcium to enter the cell and trigger the molecular cascades that consolidate synaptic change. In early Alzheimer’s disease, pathological levels of amyloid-β peptide (Aβ) bind to NMDA receptors and drive excessive activation, ultimately disrupting the delicate balance between potentiation and depression that memory storage requires.

Previous experimental work had shown that pharmacologically blocking GluN2B-containing NMDA receptors with the antagonist ifenprodil could rescue impaired LTP in CA1 pyramidal neurons exposed to Aβ. Computational models at the single-neuron level had further elucidated the biophysical mechanisms underlying this rescue. But whether these cellular-level mechanisms remain effective when synaptic impairments are distributed across a population of neurons—and how they ultimately affect memory storage and recall at a network level—could not be readily addressed experimentally. The new study by Fabio Librizzi, Saana Seppälä, Marja-Leena Linne, Michele Migliore, and Ausra Saudargiene set out to answer exactly that question.

The researchers built their model on a well-established CA1 network architecture comprising 100 hippocampal CA1 pyramidal neurons with four types of inhibitory interneurons: oriens-lacunosum moleculare, basket, bistratified, and axo-axonic cells. Each CA1 neuron was modeled with 15 compartments reflecting the soma, axon, and dendritic regions. The network receives excitatory inputs from the entorhinal cortex (EC) and CA3 Schaffer collaterals, activated by gamma bursts (30–80 Hz) coupled with a theta rhythm (4–8 Hz), mirroring the oscillatory patterns that govern memory encoding in the living brain. Each CA3 input creates two synaptic connections on the proximal dendrites of each CA1 neuron—one AMPA-mediated and one NMDA-mediated—while EC inputs arrive 9 milliseconds earlier and form AMPA-mediated connections on distal dendrites.

To simulate early Alzheimer’s pathology, the team modeled the effects of accumulated Aβ by reducing synaptic density to 80 percent of its original value, increasing free glutamate concentration to 120 percent, and modifying the shape of the GluN2B-dependent LTP function so that potentiation was abolished even when the subunit was activated. These adjustments, grounded in prior electrophysiological observations, produced a strong inhibition of LTP and a complete lack of synaptic weight increase during the storage protocol. The researchers then tested whether partially blocking GluN2B function could restore the impaired plasticity.

The results were striking. Reducing GluN2B conductivity to 40 percent of its original value produced a recovery of roughly 90 percent of the original synaptic weight increase during the 25-second storage protocol. The recovery fraction depended strongly on the degree of GluN2B attenuation, with 0.4 microsiemens providing the maximum rescue for the network. Importantly, control simulations in which AMPA receptor conductance was reduced across a range of values produced no recovery whatsoever, confirming that the rescue is specific to the GluN2B-dependent mechanism rather than reflecting a nonspecific reduction of excitatory drive. This specificity aligns with the known role of GluN2B–NMDAR-dependent calcium/calmodulin kinase II (CaMKII) signaling in Aβ-induced LTP disruption.

The team then evaluated network performance in storing and retrieving multiple patterns, both orthogonal (non-overlapping) and non-orthogonal (overlapping). With 100 CA1 cells and 20-input patterns, a maximum of five orthogonal patterns could be presented. Recall quality was nearly perfect for orthogonal patterns, as expected, since they activate entirely separate sets of synapses. For non-orthogonal patterns, quality decreased even with only five stored patterns, mainly due to spurious spiking of cells not involved in the recalled pattern. When 50 non-orthogonal patterns were stored, recall quality approached the threshold corresponding to the spiking of all 100 CA1 neurons—effectively rendering the output uninformative about which memory was retrieved.

When the researchers introduced different fractions of AD-affected synapses—0, 20, 50, 80, and 100 percent—they found that recall quality decreased significantly as the fraction of impaired cells increased. However, reducing GluN2B activity to 40 percent of its original value strongly counteracted this effect, to the point that in rescue conditions the quality factor almost approached its maximum value even when 100 percent of synapses were AD-affected. For non-orthogonal patterns, the partial GluN2B inhibition appeared to reduce spurious spiking of cells outside the recalled pattern, improving recall specificity, although it simultaneously reduced the average number of spikes, weakening quality in some cases. The interplay between these two effects produced a nuanced network-level outcome that could not have been predicted from single-synapse mechanisms alone.

The authors emphasize that the degree of recovery depends on population-level variables such as the fraction of affected CA1 neurons and the structure of the stored patterns. The model’s robust behavior across different levels of synaptic impairment and pattern separation supports the presented mechanisms for synaptic recovery in Alzheimer’s-like conditions. The results indicate that accumulated Aβ disrupts GluN2B function in hippocampal microcircuits, impairing memory storage and recall especially by affecting theta-gamma coupling, which can be partly restored by suppressing GluN2B conductivity.

While no specific GluN2B antagonist has yet been approved as a therapeutic agent for Alzheimer’s disease, unspecific NMDA receptor antagonists such as memantine have received FDA approval for their modest symptomatic effects. The new findings provide a proof-of-concept that selective GluN2B blockade could counteract early AD impairments not only at the single-neuron level but also at the network level in memory storage and recall. The authors stress that the 40 percent reduction identified here should not be considered a universal optimum, but rather that an intermediate level of GluN2B activity exists that optimally restores LTP under the conditions studied. Future work incorporating astrocytic dynamics and other molecular mechanisms into large-scale network models could further elucidate how early synaptic dysfunction propagates to network-level deficits and how targeted interventions can restore function in Alzheimer’s disease.

Subject of Research: Network-level restoration of impaired memory function in early Alzheimer’s disease via GluN2B modulation: insights from a hippocampal CA1–CA3 model

Article Title: Network-level restoration of impaired memory function in early Alzheimer’s disease via GluN2B modulation: insights from a hippocampal CA1–CA3 model

Article References: Librizzi, F., Seppälä, S., Linne, M.-L., Migliore, M., & Saudargiene, A. (2026). Network-level restoration of impaired memory function in early Alzheimer’s disease via GluN2B modulation: insights from a hippocampal CA1–CA3 model. Frontiers in Computational Neuroscience, 20, Article 1953352. https://doi.org/10.3389/fncom.2026.1953352

Image Credits: AI Generated

DOI: 10.3389/fncom.2026.1953352

Keywords: Network-level, restoration, impaired, memory, function, early, Alzheimer, disease, GluN2B, modulation, insights, hippocampal

The research, published in Frontiers in Aging, analyzed autophagy flux in primary skin fibroblasts from apparently healthy male donors aged 20, 38, 74, and 96 years. Fibroblasts are a widely adopted aging cell system because they retain the cellular and molecular signatures of their donors: the skin is directly exposed to ultraviolet radiation, pollutants, and genotoxic agents over a lifetime, so fibroblasts from older individuals carry the in vivo wear of their chronological age into a controlled culture dish. By comparing cells across this age range, the team could trace how each phase of autophagy changes as human cells grow old.

Autophagy is a multi-step assembly line. Under starvation signaling, inhibition of mTOR activates the ULK1/2 kinase complex, which nucleates a phagophore. Two ubiquitin-like conjugation systems, ATG12/ATG5/ATG16L and LC3, elongate and seal the membrane into an autophagosome. The SNARE protein syntaxin 17 is then recruited to mature autophagosomes, licensing their fusion with lysosomes to form autolysosomes, where hydrolases degrade the luminal content. Because each step can fail independently, measuring flux across the whole pathway is essential for designing therapies that reactivate the specific phase that is actually broken.

The master switch of this pathway is transcription factor EB, or TFEB, which controls the expression of autophagy and lysosomal genes. Under nutrient-rich conditions, phosphorylated TFEB sits inert in the cytoplasm; during stress, calcineurin-mediated dephosphorylation drives it into the nucleus. When the researchers examined fibroblasts by confocal microscopy, TFEB activation looked surprisingly intact, even enhanced, in aging. Starvation pushed TFEB into the nuclei of cells from all donors, and the 96-year-old fibroblasts showed the strongest nuclear signal, even accumulating TFEB in the nucleus under normal, non-starved conditions.

That nuclear buildup translated into transcription. Quantitative RT-PCR showed that the TFEB target genes LAMP1, SQSTM1, and MAP1LC3B responded to starvation in cells from all ages, with SQSTM1 and MAP1LC3B transcripts rising markedly higher in the 96-year-old fibroblasts than in the 20-year-old controls. The authors interpret this premature nuclear accumulation of TFEB in old cells as a compensatory alarm: a signaling mechanism mobilized to counteract the impaired flux and lysosomal dysfunction discovered downstream. Alternative explanations, such as altered mTORC1- or ERK-mediated phosphorylation trapping TFEB in the nucleus, or an age-dependent decline in CRM1-mediated nuclear export, remain to be tested.

Autophagosome formation also held up. Treating cells with chloroquine, which blocks autophagosome-lysosome fusion, revealed LC3-positive puncta in fibroblasts from all donors, and Western blotting of the LC3-I to LC3-II conversion showed that autophagosomes formed with similar efficiency across the age spectrum. Flow cytometry with Cyto-ID dye even found a greater accumulation of autophagic vacuoles in the older cultures, implying that the early machinery operates at least as vigorously in old cells, likely as an active coping mechanism against age-related cellular stress.

The picture changed when the team probed the end of the line. The selective autophagy receptor p62, which is itself degraded in autolysosomes, normally accumulates when flux is blocked. Yet when fibroblasts were starved and treated with the lysosomal inhibitors E64D and pepstatin A, young and middle-aged cells accumulated LC3-II and p62 robustly, while cells from the 74- and 96-year-old donors showed no significant accumulation at all. The lysosome-dependent turnover of the canonical autophagy markers had decayed with age, a result the authors confirmed with bafilomycin A1, an inhibitor of the V-ATPase pump that arrests autophagosome-lysosome fusion.

Confocal colocalization assays pinpointed where the assembly line jams. In young fibroblasts, starvation significantly increased the overlap between LC3 and syntaxin 17, indicating enhanced autophagosome maturation, with Pearson correlation coefficients rising from 0.35 to 0.63. In old fibroblasts, starvation produced no such increase, with coefficients of 0.42 versus 0.39. Similarly, the colocalization of LC3 with the lysosomal membrane protein LAMP1, an indicator of autophagosome-lysosome fusion, rose sharply in young cells under starvation but only marginally in aged cells. The final two steps of autophagy, maturation and fusion, had quietly failed.

The culprit appears to be the lysosome itself. LysoBrite staining revealed that fibroblasts from the oldest donor carried a significantly increased abundance of lysosomes, and starvation enlarged lysosomes in all cultures, with the most expanded organelles in the 74- and 96-year-old cells. These enlarged lysosomes were unresponsive to autophagy induction: the 96-year-old fibroblasts showed the greatest basal lysosomal activity but failed to activate it further under starvation, unlike cells from younger donors. Consistent with overloaded, dysfunctional organelles, lipofuscin, the non-degradable autofluorescent pigment formed by incomplete lysosomal digestion, accumulated heavily in the oldest fibroblasts, and starvation could clear it in young cells but not in old ones.

The findings carry a clear therapeutic message. Rather than simply switching autophagy on, interventions in aging may need to target the final steps of the pathway: TFEB activators to stimulate lysosomal biogenesis through the CLEAR gene network, mTOR inhibitors such as rapamycin to restore flux, and lysosomal acidification enhancers, from small molecules to acidic nanoparticles, to boost enzymatic activity. The authors acknowledge that a single donor per age group limits generalizability, and future studies with additional donors will be needed to confirm whether late-stage autophagy impairment is a universal hallmark of fibroblast aging. But the core conclusion stands: in old human cells, the recycling plant’s opening hours are fine; it is the crusher at the end of the line that has broken down.

Subject of Research: Impaired autophagy flux and lysosome dysfunction in aged human fibroblasts

Article Title: Impaired autophagy and lysosome function in human fibroblast aging

Article References: Unzueta-Mendoza, J. J., García-Aguirre, I., Königsberg, M., Arrieta-Cruz, I., Lizcano-Meneses, S., Magaña, J. J., Alarcón-Aguilar, A., & Cisneros, B. (2026). Impaired autophagy and lysosome function in human fibroblast aging. Frontiers in Aging, 7, Article 1971981. https://doi.org/10.3389/fragi.2026.1971981

Image Credits: AI Generated

DOI: 10.3389/fragi.2026.1971981

Keywords: autophagy, lysosomes, TFEB, fibroblast aging, lipofuscin, autophagosome-lysosome fusion, LC3, p62, cellular recycling, aging biology, Impaired, lysosome

PCOS is one of the most common endocrine disorders affecting women of reproductive age, characterized by irregular ovulation, clinical or biochemical signs of elevated androgens, and the presence of polycystic ovarian morphology. A hallmark of the condition is an excess of small, arrested follicles that fail to reach developmental maturity, a phenomenon known as follicular arrest. Anti-Müllerian hormone, or AMH, is often elevated in PCOS patients because of the abundance of small growing follicles, and it has become a valuable biomarker for diagnosis and disease severity. Yet the cellular reasons why these follicles stall remain incompletely understood. Because granulosa cells supply the developing follicle with energy, growth factors, and vascular signals, they represent a logical place to look for the roots of this arrest.

To investigate, the team isolated granulosa cells from women undergoing in vitro fertilization at a single center, applying the Rotterdam criteria to diagnose PCOS. The final cohort consisted of a control group of twelve women whose serum AMH levels fell within the normal range of 2 to 5 nanograms per milliliter, and a PCOS group of eleven women who met the Rotterdam criteria and displayed elevated AMH above 5 nanograms per milliliter. To control for the possibility that differences might simply reflect follicle size rather than disease, the researchers further subdivided cells from both groups according to follicular diameter, comparing cells from large follicles exceeding 14 millimeters with those from small follicles under 14 millimeters. All cells were cultured under standardized laboratory conditions, allowing the team to compare morphology, proliferation, mitochondrial activity, and secretory function directly.

The results were consistent across several independent lines of measurement. Under the microscope, PCOS-derived granulosa cells displayed abnormal morphology and an enlarged cell size compared with cells from healthy controls. When their capacity to divide was assessed, the PCOS cells proliferated significantly more slowly. This impaired growth is particularly consequential because granulosa cell proliferation drives follicle expansion during development; cells that cannot multiply properly cannot support a follicle’s progression toward ovulation. The finding suggests that the follicular arrest characteristic of PCOS may begin within the somatic compartment of the follicle rather than being solely an oocyte problem.

Deeper analysis revealed where the cellular failure likely originates: the mitochondria. These organelles serve as the cell’s power plants, generating adenosine triphosphate, or ATP, the chemical currency that fuels virtually every energy-demanding process, including cell division, protein synthesis, and secretion. The researchers found that both mitochondrial function and intracellular ATP levels were significantly reduced in PCOS granulosa cells. This energy deficit provides a coherent explanation for the observed proliferation defect, as cells with insufficient ATP cannot sustain the biosynthetic workload required to replicate. Mitochondrial dysfunction in granulosa cells has been suspected in PCOS before, but linking it quantitatively to both proliferative failure and secretory impairment in the same cohort strengthens the case that it is a central defect rather than an incidental finding.

Perhaps the most novel component of the study concerns angiogenesis, the formation of new blood vessels, which is essential for follicle development. A growing follicle depends on a rich vascular network to receive oxygen, nutrients, and hormones from the bloodstream. Granulosa cells contribute to building this network indirectly through paracrine signaling, releasing factors that stimulate nearby endothelial cells to organize into vessel structures. To test this function, the team collected conditioned media, essentially the liquid culture environment in which the granulosa cells had been growing, and applied it to human umbilical vein endothelial cells in a tube formation assay, a standard laboratory test of angiogenic capacity. The conditioned media from PCOS granulosa cells significantly impaired the ability of endothelial cells to form tubes, demonstrating that the angiogenic support normally provided by these ovarian cells was diminished in the disease state.

The effect was not uniform across follicle sizes. Granulosa cells harvested from larger follicles showed a more pronounced impairment in angiogenic support than those from smaller follicles, an observation that could help explain why larger follicles in PCOS ovaries so often fail to progress to ovulation despite reaching substantial size. At the molecular level, the researchers examined the expression of angiogenesis-related cytokines and found that three key pro-angiogenic chemokines, CXCL6, IL8, and MCP1, were consistently downregulated in PCOS granulosa cells. Interestingly, vascular endothelial growth factor A, or VEGF-A, the most famous angiogenic factor, showed a less consistent pattern, suggesting that the angiogenic deficit in PCOS is not simply a matter of reduced VEGF but rather a broader disruption of the chemokine-mediated signaling network that coordinates blood vessel formation.

Taken together, the findings sketch a coherent mechanistic framework for how PCOS disrupts follicle development. Mitochondrial dysfunction reduces ATP availability, which in turn limits cellular proliferation and dampens the secretion of angiogenic chemokines. Reduced angiogenic signaling compromises the vascular supply to developing follicles, depriving both the granulosa cells and the oocyte of the metabolic support needed for maturation. The authors describe this as a functional interplay between metabolic dysfunction and disrupted chemokine-mediated angiogenic signaling, a chain of causation that connects the metabolic phenotype of PCOS to its reproductive consequences. Because the chemokines CXCL6, IL8, and MCP1 emerged as consistently downregulated factors, they represent plausible targets for interventions aimed at restoring follicular vascular support in affected women.

The study carries practical implications for fertility medicine. Many women with PCOS require assisted reproductive technology to conceive, and the quality of the follicular environment is a determinant of oocyte competence and embryo development. If the granulosa cell dysfunction identified here proves to be modifiable, strategies to improve mitochondrial function or replenish angiogenic chemokine signaling could theoretically enhance follicle quality in PCOS patients undergoing IVF. Such approaches remain speculative, and the study is a relatively small observational analysis conducted at a single center, so the findings will need replication in larger and more diverse cohorts before they translate into clinical protocols. The authors note that the work provides potential targets for improving reproductive outcomes rather than an immediate treatment.

Beyond its clinical relevance, the study contributes to a growing appreciation of the ovary as a metabolically demanding organ in which cellular energy status and developmental signaling are tightly intertwined. The follicle is often studied primarily through its hormonal and genetic regulation, but this research underscores that the physical infrastructure of follicle growth, from mitochondrial ATP production to the surrounding vasculature, may be equally decisive. For the millions of women living with PCOS worldwide, a condition that remains among the leading causes of anovulatory infertility, understanding that their follicles may be starved of both energy and vascular support offers a new dimension to the search for causes and cures. As research continues to map the molecular pathways linking mitochondrial health, chemokine signaling, and folliculogenesis, the granulosa cell may well emerge as a key gateway through which future therapies for PCOS are delivered.

The study was conducted under ethical oversight at Cathay General Hospital in Taipei, with approval from the hospital’s Ethics Committee and written informed consent obtained from all participants, in accordance with the Declaration of Helsinki. The work received financial support from the National Science and Technology Council of Taiwan and from Cathay General Hospital, and the authors declared no competing interests.

Readers should note that the article was published as an accepted manuscript in open access form, released early to provide faster access to peer-reviewed research. This version is citable and carries a permanent DOI, though it remains subject to editorial revisions before the final Version of Record replaces it. The research is categorized under topics including endocrine reproductive disorders, fertility, and gonadal disorders, reflecting its position at the intersection of reproductive endocrinology and cellular metabolism research.

Subject of Research: Mitochondrial dysfunction in granulosa cells is associated with impaired proliferation and angiogenic support in women with polycystic ovarian syndrome and elevated AMH

Article Title: Mitochondrial dysfunction in granulosa cells is associated with impaired proliferation and angiogenic support in women with polycystic ovarian syndrome and elevated AMH

Article References: Hong, K.-J., Lin, J.-J., & Lai, T.-H. (2026). Mitochondrial dysfunction in granulosa cells is associated with impaired proliferation and angiogenic support in women with polycystic ovarian syndrome and elevated AMH. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02264-x

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02264-x

Keywords: Mitochondrial, dysfunction, granulosa, cells, associated, impaired, proliferation, angiogenic, support, women, polycystic, ovarian